Future perspectives of treatment for anemia in chronic kidney disease (CKD) using hypoxia-inducible factor prolyl hydroxylase inhibitors

DOI Web Site PubMed
  • NANGAKU Masaomi
    Division of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine

Bibliographic Information

Other Title
  • HIF-PH阻害薬が切り拓く新しい腎性貧血治療
  • HIF-PH ソガイヤク ガ キリ ヒラク アタラシイジンセイ ヒンケツ チリョウ

Search this article

Description

<p>Oxygen biology is currently a focus of intensive scientific research. Three scientists received the Nobel prize in physiology or medicine for their outstanding scientific efforts in revealing the mechanisms of oxygen sensing and defense against hypoxia. Hypoxia is a final common pathway to end-stage kidney disease and plays a crucial role in the pathogenesis of cardiovascular complications. Hypoxia-inducible factors (HIFs) are master regulators of defensive mechanisms against hypoxia. Erythropoietin is one of the main targets of HIFs that enhances oxygen delivery by increasing the production of red blood cells. HIF levels are regulated by HIF-prolyl hydroxylase (HIF-PH) inhibitors, which are now available as a new therapeutic modality against anemia in chronic kidney disease. HIF-PH inhibitors raise some theoretical concerns, but should be noted for their potential organ-protective effects.</p>

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 62 (8), 938-943, 2021

    The Japanese Society of Hematology

Keywords

Details 詳細情報について

Report a problem

Back to top